ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Below 50 Day Moving Average – Time to Sell?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $84.30 and traded as low as $83.36. ProShares Ultra Nasdaq Biotechnology shares last traded at $83.88, with a volume of 3,351 shares.

ProShares Ultra Nasdaq Biotechnology Stock Down 1.4%

The stock has a 50-day moving average of $84.30 and a 200 day moving average of $74.55. The stock has a market cap of $88.07 million, a PE ratio of 20.68 and a beta of 1.38.

ProShares Ultra Nasdaq Biotechnology Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Wednesday, December 24th were issued a $0.1346 dividend. This represents a $0.54 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, December 24th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Laurel Wealth Advisors LLC lifted its position in ProShares Ultra Nasdaq Biotechnology by 4,481.0% during the second quarter. Laurel Wealth Advisors LLC now owns 13,743 shares of the exchange traded fund’s stock valued at $630,000 after purchasing an additional 13,443 shares during the period. Palumbo Wealth Management LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 3rd quarter worth about $766,000. Kaizen Financial Strategies acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth about $424,000. Citadel Advisors LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 3rd quarter valued at about $307,000. Finally, Franklin Resources Inc. acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology in the 2nd quarter valued at about $32,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.